StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

RPRX — Royalty Pharma plc

UNDERVALUED (MOS +60.3%) · Quality 45/100

Price
58.41
Intrinsic value
147.19
Margin of safety
+60.3%
Implied growth (reverse DCF)
-6.8%
model assumes +5.1%
Value Score
34.7
Quality
45
Psychology
8.7
Discovery
23.5
price/volume attention only
Moat score
42
erosion: none

Value Score: bottom 47% of Russell 3000 · Quality: bottom 9%

Dividend: 0.925/share (TTM) · yield 1.6% · payout 49%

Open the interactive Deep Dive for RPRX →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/RPRX - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is RPRX undervalued?

As of 2026-09-19, RPRX trades at 58.41 against a computed intrinsic value of 147.19 (+60.3% margin of safety) - StocksDeepDive's valuation label for this is UNDERVALUED. This is a described calculation from public data, not a recommendation.

What is Royalty Pharma plc's Value Score?

Royalty Pharma plc's Value Score is 34.7 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.

Does RPRX pay a dividend?

Yes - RPRX's trailing twelve-month dividend is 0.925/share, a yield of 1.6% at the current price (as of 2026-09-19).